全文获取类型
收费全文 | 64430篇 |
免费 | 4759篇 |
国内免费 | 1394篇 |
专业分类
耳鼻咽喉 | 986篇 |
儿科学 | 2239篇 |
妇产科学 | 996篇 |
基础医学 | 7800篇 |
口腔科学 | 1050篇 |
临床医学 | 4801篇 |
内科学 | 11522篇 |
皮肤病学 | 1064篇 |
神经病学 | 14709篇 |
特种医学 | 1482篇 |
外国民族医学 | 10篇 |
外科学 | 5786篇 |
综合类 | 3722篇 |
现状与发展 | 3篇 |
一般理论 | 4篇 |
预防医学 | 3569篇 |
眼科学 | 1141篇 |
药学 | 5214篇 |
14篇 | |
中国医学 | 2172篇 |
肿瘤学 | 2299篇 |
出版年
2023年 | 1252篇 |
2022年 | 1667篇 |
2021年 | 3366篇 |
2020年 | 3095篇 |
2019年 | 3717篇 |
2018年 | 3566篇 |
2017年 | 2958篇 |
2016年 | 2328篇 |
2015年 | 2295篇 |
2014年 | 4835篇 |
2013年 | 6272篇 |
2012年 | 3841篇 |
2011年 | 3817篇 |
2010年 | 2938篇 |
2009年 | 2735篇 |
2008年 | 2590篇 |
2007年 | 2054篇 |
2006年 | 1673篇 |
2005年 | 1386篇 |
2004年 | 1433篇 |
2003年 | 1208篇 |
2002年 | 954篇 |
2001年 | 790篇 |
2000年 | 763篇 |
1999年 | 630篇 |
1998年 | 544篇 |
1997年 | 559篇 |
1996年 | 248篇 |
1995年 | 286篇 |
1994年 | 279篇 |
1993年 | 260篇 |
1992年 | 191篇 |
1991年 | 189篇 |
1990年 | 157篇 |
1989年 | 132篇 |
1988年 | 119篇 |
1987年 | 98篇 |
1985年 | 644篇 |
1984年 | 753篇 |
1983年 | 500篇 |
1982年 | 568篇 |
1981年 | 500篇 |
1980年 | 405篇 |
1979年 | 386篇 |
1978年 | 331篇 |
1977年 | 245篇 |
1976年 | 243篇 |
1975年 | 247篇 |
1974年 | 192篇 |
1973年 | 197篇 |
排序方式: 共有10000条查询结果,搜索用时 213 毫秒
41.
《Sleep medicine》2020
ObjectivesHyperechogenicity of the substantia nigra (SN) and abnormal dopamine transporter-single-photon emission computed tomography (DAT-SPECT) are biomarkers commonly used in the assessment of prodromal synucleinopathy. Our goals were as follows: (1) to compare echogenicity of SN in idiopathic rapid eye movement (REM) behavior disorder (iRBD), Parkinson's disease (PD) without RBD (PD-noRBD), PD with RBD (PD + RBD), and control subjects; and (2) to examine association between SN degeneration assessed by DAT-SPECT and SN echogenicity.Patients/methodsA total of 61 subjects with confirmed iRBD were examined using Movement Disorders Society-unified PD rating scale (MDS-UPDRS), TCS (transcranial sonography) and DAT-SPECT. The results were compared with 44 patients with PD (25% PD + RBD) and with 120 age-matched healthy subjects.Results and conclusionThe abnormal SN area was found in 75.5% PD, 23% iRBD and 7.3% controls. Median SN echogenicity area in PD (0.27 ± 0.22 cm2) was higher compared to iRBD (0.07 ± 0.07 cm2; p < 0.0001) and controls (0.05 ± 0.03 cm2; p < 0.0001). SN echogenicity in PD + RBD was not significantly different from PD-noRBD (0.30 vs. 0.22, p = 0.15).Abnormal DAT-SPECT was found in 16 iRBD (25.4%) and 44 PD subjects (100%). No correlation between the larger SN area and corresponding putaminal binding index was found in iRBD (r = −0.13, p = 0.29), nor in PD (r = −0.19, p = 0.22).The results of our study showed that: (1) SN echogenicity area in iRBD was higher compared to controls, but the hyperechogenicity was present only in a minority of iRBD patients; (2) SN echogenicity and DAT-SPECT binding index did not correlate in either group; and (3) SN echogenicity does not differ between PD with/without RBD. 相似文献
42.
43.
44.
Joobin Sattar Adi Kartolo Wilma M. Hopman Joshua Matthew Lakoff Tara Baetz 《Journal of Geriatric Oncology》2019,10(3):411-414
ImportanceImmunotherapy has emerged as an effective treatment option for the management of advanced cancers. The effects of these immune checkpoint inhibitors in the older patient population has not been adequately assessed.ObjectiveTo understand the impact of aging on CTLA-4 and PDL-1 inhibitors efficacy and immune-related adverse events (irAE) in the context of real-world management of advanced solid cancers.Design, Setting, and ParticipantsThis retrospective study involved all non-study patients with histologically-confirmed metastatic or inoperable solid cancers receiving immunotherapy at Kingston Health Sciences Centre. We defined ‘older patient’ as age ≥ 75. All statistical analyses were conducted under SPSS IBM for Windows version 24.0.Main Outcomes and MeasuresStudy outcomes included immunotherapy treatment response, survival, as well as number, type, and severity of irAEs.ResultsOur study (N = 78) had 29 (37%) patients age <65, 26 (33%) patients age 65–74, and 23 (30%) patients age ≥75. Melanoma, non-small cell lung cancer, and renal cell carcinoma accounted for 70%, 22%, and 8% of the study population, respectively. Distributions of ipilimumab (32%), nivolumab (33%), and pembrolizumab (35%) were similar in the study. The response rates were 28%, 27%, and 39% in the age <65, age 64–74, age ≥75 groups, respectively (P = 0.585). Kaplan-Meier curve showed a median survival of 28 months (12.28–43.9, 95% CI) and 17 months (0–36.9, 95% CI) in the age <65 and age 64–74 groups, respectively; the estimated survival probability did not reach 50% in the age ≥75 group (P = 0.319). There were no statistically significant differences found in terms of irAEs, multiple irAEs, severity of grade 3 or higher, types of irAEs, and irAEs resolution status when comparing between different age groups.Conclusion and RelevanceOur results suggest that patients age ≥75 are able to gain as much benefit from immunotherapy as younger patients, without excess toxicity. Our findings suggest that single agent immunotherapy is generally well-tolerated across different age groups with no significant difference in the type, frequency or severity of irAEs. Future studies evaluating aging and combination immunotherapy are warranted. 相似文献
45.
《Drug discovery today》2022,27(6):1733-1742
Compounds that exhibit assay interference or undesirable mechanisms of bioactivity are routinely encountered in assays at various stages of drug discovery. We observed that assays for the investigation of thiol-reactive and redox-active compounds have not been collected in a comprehensive review. Here, we review these assays and subject them to experimental optimization to improve their reliability. We demonstrate the usefulness of our assay cascade by assaying a library of bioactive compounds, chemical probes, and a set of approved drugs. These high-throughput assays should complement the array of wet-lab and in silico assays during the initial stages of hit discovery campaigns to pursue only hit compounds with tractable mechanisms of action. 相似文献
46.
47.
48.
Salvatore Greco Beatrice Bonsi Nicol Fabbri 《World Journal of Experimental Medicine》2022,12(5):104-107
Even if the relationships between nutrition and inflammatory bowel disease (IBD) remain underexplored, the current literature is providing, day by day, much more evidence on the effects of various diets in both prevention and treatment of such illnesses. Wrong dietary habits, together with other environmental factors such as pollution, breastfeeding, smoke, and/or antibiotics, are among the theoretical pathogenetic causes of IBD, whose multifactorial aetiology has been already confirmed. While some of these risk factors are potentially reversible, some others cannot be avoided, and efficient treatments become necessary to prevent IBD spread or recurrence. Furthermore, the drugs currently available for treatment of such disease provide low-to-no effect against the symptoms, making the illnesses still strongly disabling. Whether nutrition and specific diets will prove to effectively interrupt the course of IBD has still to be clarified and, in this sense, further research concerning the applications of such dietary interventions is still needed. 相似文献
49.